Management of infants with chronic lung disease of prematurity in the United Kingdom

Early Hum Dev. 2005 Feb;81(2):165-70. doi: 10.1016/j.earlhumdev.2004.12.008. Epub 2005 Jan 16.

Abstract

The management of chronic lung disease of prematurity (CLD) is challenging for the neonatologist. There are few well-powered randomised controlled trials to inform practice and longer-term outcomes of some interventions have only recently been identified (for example the possible association between the use of corticosteroids and neurodevelopmental abnormalities). As a result, many neonatologists rely on empirical management derived from the evidence available. We describe, in this article, our own approach to the management of CLD, and acknowledge that practice may vary between units within the United Kingdom.

Publication types

  • Review

MeSH terms

  • Adrenal Cortex Hormones / therapeutic use
  • Ambulatory Care / methods
  • Bronchodilator Agents / therapeutic use
  • Bronchopulmonary Dysplasia / therapy*
  • Chronic Disease
  • Diuretics
  • Humans
  • Infant, Newborn
  • Infant, Premature
  • Oxygen Inhalation Therapy / methods*
  • Respiratory Distress Syndrome, Newborn / therapy*
  • United Kingdom

Substances

  • Adrenal Cortex Hormones
  • Bronchodilator Agents
  • Diuretics